About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Artm1.1Chc
targeted mutation 1.1, Chawnshang Chang
MGI:2687199
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
 		Artm1.1Chc/Artm1.1Chc involves: 129S/SvEv * C57BL/6 * FVB/N MGI:3775038
cn2
 		Artm1Chc/Artm1.1Chc
Tmem163Tg(ACTB-cre)2Mrt/0 		involves: 129S/SvEv * C57BL/6J * FVB/N MGI:3773446
ot3
 		Artm1.1Chc/Y involves: 129S/SvEv * C57BL/6 * FVB/N MGI:3773633


Genotype
MGI:3775038
hm1
Allelic
Composition		 Artm1.1Chc/Artm1.1Chc
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Artm1.1Chc mutation (0 available); any Ar mutation (23 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
decreased incidence of tumors by chemical induction ( J:120844 )
• after treatment with the genotoxic bladder carcinogen BBN, no null females develop carcinomas whereas 42% of treated females have bladder carcinomas by 40 weeks post-treatment
preneoplasia ( J:120844 )
• only 2 females display preneoplastic lesions (hyperplasias) of the bladder by 40 weeks following treatment compared to 67% of wild-type females

homeostasis/metabolism
decreased incidence of tumors by chemical induction ( J:120844 )
• after treatment with the genotoxic bladder carcinogen BBN, no null females develop carcinomas whereas 42% of treated females have bladder carcinomas by 40 weeks post-treatment




Genotype
MGI:3773446
cn2
Allelic
Composition		 Artm1Chc/Artm1.1Chc
Tmem163Tg(ACTB-cre)2Mrt/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6J * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Artm1.1Chc mutation (0 available); any Ar mutation (23 available)
Artm1Chc mutation (0 available); any Ar mutation (23 available)
Tmem163Tg(ACTB-cre)2Mrt mutation (3 available); any Tmem163 mutation (37 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
reproductive system
decreased ovary weight ( J:87193 )
• ovaries from 4-, 6-, and 12-week old females weigh 18-23% less than those of control females
decreased oviduct weight ( J:87193 )
• oviducts from 4-, 6-, and 12-week old females weigh 18-23% less than those of control females
decreased uterus weight ( J:87193 )
• uterI from 4-, 6-, and 12-week old females weigh 18-23% less than in control females
decreased litter size ( J:81789 )
• litters from homozygous females are have fewer pups compared to those of control females

behavior/neurological
abnormal nursing ( J:87193 )
• some mutant females display reluctant nursing behavior

endocrine/exocrine glands
enlarged thymus ( J:87193 )
• thymus in female mice is larger than in control females
abnormal mammary gland morphology ( J:87193 )
• mammary glands in 4-, 6-, and 12-week old females weigh 18-23% less than in control female littermates
abnormal branching of the mammary ductal tree ( J:87193 )
• by fourth to sixth weeks of age, ductal system has 30-50% less extension with reduced numbers of terminal end buds than in control females
• at maturity (8, 16 and 20 weeks) mammary glands are filled with large bloated ducts terminating with bloated ends; glands have fewer secondary and tertiary ductal branches compared to controls; during pregnancy, retarded ductal branches are partially restored, but mutant mammary glands still have less milk-producing alveoli than control glands
decreased ovary weight ( J:87193 )
• ovaries from 4-, 6-, and 12-week old females weigh 18-23% less than those of control females
abnormal lactation ( J:87193 )
• retardation of mammary gland development may affect capacity of females to provide milk for their offspring

hematopoietic system
enlarged thymus ( J:87193 )
• thymus in female mice is larger than in control females

immune system
enlarged thymus ( J:87193 )
• thymus in female mice is larger than in control females

integument
abnormal mammary gland morphology ( J:87193 )
• mammary glands in 4-, 6-, and 12-week old females weigh 18-23% less than in control female littermates
abnormal branching of the mammary ductal tree ( J:87193 )
• by fourth to sixth weeks of age, ductal system has 30-50% less extension with reduced numbers of terminal end buds than in control females
• at maturity (8, 16 and 20 weeks) mammary glands are filled with large bloated ducts terminating with bloated ends; glands have fewer secondary and tertiary ductal branches compared to controls; during pregnancy, retarded ductal branches are partially restored, but mutant mammary glands still have less milk-producing alveoli than control glands
abnormal lactation ( J:87193 )
• retardation of mammary gland development may affect capacity of females to provide milk for their offspring




Genotype
MGI:3773633
ot3
Allelic
Composition		 Artm1.1Chc/Y
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Artm1.1Chc mutation (0 available); any Ar mutation (23 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
reproductive system
small testis ( J:89886 )
• much smaller than wild-type and smaller than in males with Sertoli cell-specific Ar-deficiency
arrest of spermatogenesis ( J:89886 )
• spermatogenesis is arrested at the pachytene stage

endocrine/exocrine glands
small testis ( J:89886 )
• much smaller than wild-type and smaller than in males with Sertoli cell-specific Ar-deficiency

homeostasis/metabolism
decreased circulating testosterone level ( J:89886 )
• mutant males have lower serum testosterone levels than wild-type males or males with Sertoli cell-specific Ar-deficiency
increased circulating luteinizing hormone level ( J:89886 )
• LH levels are increased in serum than wild-type males
decreased incidence of tumors by chemical induction ( J:120844 )
• after treatment with the genotoxic bladder carcinogen BBN, no null males develop carcinomas whereas all wild-type males show invasive bladder carcinoma by 30 weeks after treatment
• however, treatment with BBN and dihydroxytestosterone (DHT) results in 25% of males developing bladder carcinoma by 40 weeks

neoplasm
decreased incidence of tumors by chemical induction ( J:120844 )
• after treatment with the genotoxic bladder carcinogen BBN, no null males develop carcinomas whereas all wild-type males show invasive bladder carcinoma by 30 weeks after treatment
• however, treatment with BBN and dihydroxytestosterone (DHT) results in 25% of males developing bladder carcinoma by 40 weeks
abnormal tumor morphology ( J:120844 )
• BBN-induced bladder tumors in DHT-treated males have lower proliferation indices and higher apoptotic index than BBN-treated wild-type, BBN-treated castrated wild-type malesand BBN only-treated males
preneoplasia ( J:120844 )
• only 2 males display preneoplastic lesions (hyperplasias) of the bladder by 40 weeks following treatment compared to 75% of wild-type
• however, treatment with BBN and dihydroxytestosterone (DHT) results in 40% of treated males showing preneoplastic lesions by 40 weeks




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/19/2024
MGI 6.24 		The Jackson Laboratory